MARKET

GMED

GMED

Globus Med Inc
NYSE
45.34
-0.97
-2.09%
After Hours: 45.77 +0.43 +0.95% 19:29 12/05 EST
OPEN
46.10
PREV CLOSE
46.31
HIGH
46.38
LOW
45.12
VOLUME
1.28M
TURNOVER
0
52 WEEK HIGH
80.04
52 WEEK LOW
43.39
MARKET CAP
6.25B
P/E (TTM)
29.32
1D
5D
1M
3M
1Y
5Y
Investors in Globus Medical (NYSE:GMED) have unfortunately lost 34% over the last year
Globus medical, inc. Share price is down 34% in the last year against the overall market return of 17%. The company's share price has also fallen by 24% in three years. Globus medical's long term shareholder return has not matched the performance of the underlying business. We look at the company's fundamentals to see if the stock is a good investment.
Simply Wall St · 9h ago
Weekly Report: what happened at GMED last week (1127-1201)?
Weekly Report · 2d ago
Piper sees GLP-1s increasing demand for knee/hip surgeries near-term
Healthcare piper sees glp-1s increasing demand for knee/hip surgeries near-term. Investment bank sees weight loss drugs leading to higher demand for replacements of weight-bearing joints. Piper sees a 10% increase in knee and hip surgeries in the next 7 to 10 years.
Seeking Alpha · 2d ago
Globus Med Inc: Securities to be offered to employees in employee benefit plans
Press release · 5d ago
Globus Medical: Merger Overhang Lingering
Globus medical, inc., a mid-cap medical device company, has seen its stock decline by over 35% in 2023. The company recently completed a $3 billion merger with nuvasive. Globus medical has a solid balance sheet and significant growth prospects. Analyst firms are skeptical of the purchase of nuvasive, but the company is profitable and profitable.
Seeking Alpha · 11/27 23:05
Weekly Report: what happened at GMED last week (1120-1124)?
Weekly Report · 11/27 09:04
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)
Rbc capital maintained a buy rating on globus medical (gmed – research report) with a price target of $70.00. Shagun singh chadha is an analyst with an average return of -10.4% and a 24.34% success rate. Gmed has an analyst consensus of moderate buy and a $64.17 price target.
TipRanks · 11/24 12:05
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and LAVA Therapeutics (LVTX)
TipRanks · 11/22 05:31
More
About GMED
Globus Medical, Inc. is a musculoskeletal solutions company that develops and commercializes healthcare solutions. The Company’s product categories include musculoskeletal procedural solutions and enabling technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics solutions for assisted surgery.

Webull offers Globus Medical Inc stock information, including NYSE: GMED real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMED stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMED stock methods without spending real money on the virtual paper trading platform.